Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

IMP-27, a Unique Metallo-β-Lactamase Identified in Geographically Distinct Isolates of Proteus mirabilis.

Dixon N, Fowler RC, Yoshizumi A, Horiyama T, Ishii Y, Harrison L, Geyer CN, Moland ES, Thomson K, Hanson ND.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6418-21. doi: 10.1128/AAC.02945-15. Print 2016 Oct.

2.

KPC screening by updated BD Phoenix and Vitek 2 automated systems.

Thomson KS, Robledo IE, Vázquez GJ, Moland ES.

J Clin Microbiol. 2011 Sep;49(9):3386-7. doi: 10.1128/JCM.00772-11. Epub 2011 Jul 6.

3.

First report of CTX-M-14 producing clinical isolates of Salmonella serovar Typhimurium from Egypt.

AbdelGhani SM, Moland ES, Black JA, Hanson ND, Goering RV, Amine MA, Saafan AE, Gaafar M, Younan M, Thomson KS.

J Infect Dev Ctries. 2009 Dec 14;4(1):58-60. No abstract available.

4.

Positive extended-spectrum-beta-lactamase (ESBL) screening results may be due to AmpC beta-lactamases more often than to ESBLs.

Munier GK, Johnson CL, Snyder JW, Moland ES, Hanson ND, Thomson KS.

J Clin Microbiol. 2010 Feb;48(2):673-4. doi: 10.1128/JCM.01544-09. Epub 2009 Dec 2. No abstract available.

5.

Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.

Hanson ND, Moland ES, Hong SG, Propst K, Novak DJ, Cavalieri SJ.

Antimicrob Agents Chemother. 2008 Oct;52(10):3814-6. doi: 10.1128/AAC.00877-08. Epub 2008 Jul 28.

6.

In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.

Moland ES, Craft DW, Hong SG, Kim SY, Hachmeister L, Sayed SD, Thomson KS.

Antimicrob Agents Chemother. 2008 Aug;52(8):2940-2. doi: 10.1128/AAC.01581-07. Epub 2008 Jun 2.

7.

Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains.

Thomson KS, Black J, Moland ES, Reuben J, Wiles T, Brasso W.

Int J Antimicrob Agents. 2008 Jan;31(1):83-5. Epub 2007 Nov 8. No abstract available.

PMID:
17996426
8.
9.

Convenient test using a combination of chelating agents for detection of metallo-beta-lactamases in the clinical laboratory.

Kim SY, Hong SG, Moland ES, Thomson KS.

J Clin Microbiol. 2007 Sep;45(9):2798-801. Epub 2007 Jun 27.

10.

In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.

Hong SG, Moland ES, Wickman PA, Black JA, Hossain A, Hanson ND, Thomson KS.

Antimicrob Agents Chemother. 2007 Apr;51(4):1512-4. Epub 2007 Jan 12.

11.

Klebsiella pneumoniae isolate producing at least eight different beta-lactamases, including AmpC and KPC beta-lactamases.

Moland ES, Hong SG, Thomson KS, Larone DH, Hanson ND.

Antimicrob Agents Chemother. 2007 Feb;51(2):800-1. Epub 2006 Dec 4. No abstract available.

12.

Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.

Moland ES, Hanson ND, Black JA, Hossain A, Song W, Thomson KS.

J Clin Microbiol. 2006 Sep;44(9):3318-24.

13.

First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-beta-lactamase, IMP-18.

Hanson ND, Hossain A, Buck L, Moland ES, Thomson KS.

Antimicrob Agents Chemother. 2006 Jun;50(6):2272-3. No abstract available.

14.

In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.

Wickman PA, Black JA, Moland ES, Thomson KS.

Antimicrob Agents Chemother. 2006 Jun;50(6):2255-7.

15.
16.

Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase.

Alba J, Ishii Y, Thomson K, Moland ES, Yamaguchi K.

Antimicrob Agents Chemother. 2005 Nov;49(11):4760-2.

17.

Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.

Song W, Moland ES, Hanson ND, Lewis JS, Jorgensen JH, Thomson KS.

J Clin Microbiol. 2005 Sep;43(9):4891-4.

18.
19.

New quality control strain for use in routine testing for production of extended-spectrum Beta-lactamases by enterobacteriaceae.

Mortensen JE, Bernier M, Gray LD, Dolan S, Hanson ND, Moland ES, Abdalhamid B.

J Clin Microbiol. 2005 May;43(5):2545. No abstract available.

20.

Escherichia coli: development of carbapenem resistance during therapy.

Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Sloan C, Fabian D, Farajallah A, Levine J, Thomson KS.

Clin Infect Dis. 2005 May 15;40(10):e84-6. Epub 2005 Apr 13.

PMID:
15844056
21.

Cefdinir: an oral alternative to parenteral cephems.

Chatterjee A, Moland ES, Thomson KS.

Diagn Microbiol Infect Dis. 2005 Apr;51(4):259-64.

PMID:
15808317
22.

Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp.

Hossain A, Ferraro MJ, Pino RM, Dew RB 3rd, Moland ES, Lockhart TJ, Thomson KS, Goering RV, Hanson ND.

Antimicrob Agents Chemother. 2004 Nov;48(11):4438-40.

23.

Community-onset disease caused by Citrobacter freundii producing a novel CTX-M beta-lactamase, CTX-M-30, in Canada.

Abdalhamid B, Pitout JD, Moland ES, Hanson ND.

Antimicrob Agents Chemother. 2004 Nov;48(11):4435-7.

24.
25.

NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America.

Pottumarthy S, Moland ES, Juretschko S, Swanzy SR, Thomson KS, Fritsche TR.

Emerg Infect Dis. 2003 Aug;9(8):999-1002. Erratum in: Emerg Infect Dis. 2003 Sep;9(9):1188.

26.

Discovery of CTX-M-like extended-spectrum beta-lactamases in Escherichia coli isolates from five US States.

Moland ES, Black JA, Hossain A, Hanson ND, Thomson KS, Pottumarthy S.

Antimicrob Agents Chemother. 2003 Jul;47(7):2382-3. No abstract available.

27.

Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals.

Moland ES, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson KS.

Antimicrob Agents Chemother. 2002 Dec;46(12):3837-42.

28.

Unusual Salmonella enterica serotype Typhimurium isolate producing CMY-7, SHV-9 and OXA-30 beta-lactamases.

Hanson ND, Moland ES, Hossain A, Neville SA, Gosbell IB, Thomson KS.

J Antimicrob Chemother. 2002 Jun;49(6):1011-4.

PMID:
12039894
29.

BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae.

Sanders CC, Ehrhardt AF, Moland ES, Thomson KS, Zimmer B, Roe DE.

J Clin Microbiol. 2002 Jan;40(1):123-7.

30.
31.

Activity of faropenem against resistant isolates of Streptococcus pneumoniae.

Black JA, Moland ES, Chartrand SA, Thomson KS.

Diagn Microbiol Infect Dis. 2001 Sep-Oct;41(1-2):89-92.

PMID:
11687320
32.

Potential impact of the VITEK 2 system and the Advanced Expert System on the clinical laboratory of a university-based hospital.

Sanders CC, Peyret M, Moland ES, Cavalieri SJ, Shubert C, Thomson KS, Boeufgras JM, Sanders WE Jr.

J Clin Microbiol. 2001 Jul;39(7):2379-85.

33.

Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.

Black J, Moland ES, Chartrand SA, Thomson KS.

Diagn Microbiol Infect Dis. 2001 Mar;39(3):195-7.

PMID:
11337189
35.

Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Sanders CC, Peyret M, Moland ES, Shubert C, Thomson KS, Boeufgras JM, Sanders WE Jr.

J Clin Microbiol. 2000 Feb;38(2):570-4.

36.

Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.

Pong A, Thomson KS, Moland ES, Chartrand SA, Sanders CC.

J Antimicrob Chemother. 1999 Nov;44(5):621-7.

PMID:
10552978
37.

Molecular characterization of a multiply resistant Klebsiella pneumoniae encoding ESBLs and a plasmid-mediated AmpC.

Hanson ND, Thomson KS, Moland ES, Sanders CC, Berthold G, Penn RG.

J Antimicrob Chemother. 1999 Sep;44(3):377-80.

PMID:
10511405
39.
41.
43.

Beta-lactamases and detection of beta-lactam resistance in Enterobacter spp.

Pitout JD, Moland ES, Sanders CC, Thomson KS, Fitzsimmons SR.

Antimicrob Agents Chemother. 1997 Jan;41(1):35-9.

44.

Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test.

Sanders CC, Barry AL, Washington JA, Shubert C, Moland ES, Traczewski MM, Knapp C, Mulder R.

J Clin Microbiol. 1996 Dec;34(12):2997-3001.

45.

Colonization with penicillin-nonsusceptible Streptococcus pneumoniae in urban and rural child-care centers.

Boken DJ, Chartrand SA, Moland ES, Goering RV.

Pediatr Infect Dis J. 1996 Aug;15(8):667-72.

PMID:
8858669
46.

Cefepime : The Last Generation or the First Enhanced-Potency Broad Spectrum Cephalosporin?

Sanders CC, Moland ES.

Clin Drug Investig. 1995 Dec;10(6):344-54. doi: 10.2165/00044011-199510060-00005.

PMID:
27519336
47.

New variant of TEM-10 beta-lactamase gene produced by a clinical isolate of proteus mirabilis.

Palzkill T, Thomson KS, Sanders CC, Moland ES, Huang W, Milligan TW.

Antimicrob Agents Chemother. 1995 May;39(5):1199-200.

48.

Extended-spectrum beta-lactamases of Enterobacteriaceae.

Moland ES, Thomson KS.

J Antimicrob Chemother. 1994 Mar;33(3):666-8. No abstract available.

PMID:
8040134
49.

Decimal assay for additivity of drugs permits delineation of synergy and antagonism.

Sanders CC, Sanders WE Jr, Moland ES.

Antimicrob Agents Chemother. 1993 Feb;37(2):260-4.

50.

Altered phenotypes associated with ampD mutations in Enterobacter cloacae.

Korfmann G, Sanders CC, Moland ES.

Antimicrob Agents Chemother. 1991 Feb;35(2):358-64.

Supplemental Content

Loading ...
Support Center